We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Scancell Holdings Plc | LSE:SCLP | London | Ordinary Share | GB00B63D3314 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 9.70 | 9.50 | 10.00 | 9.75 | 9.75 | 9.75 | 2,795,799 | 16:35:11 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 0 | -5.86M | -0.0057 | -17.11 | 100.57M |
Date | Subject | Author | Discuss |
---|---|---|---|
05/10/2024 17:32 | it all comes crashing down .... the telegraph Mr Philp explained that on Aug 30, Dr Luke Evans, a Tory MP, tabled a written question to Liz Kendall, the Work and Pensions Secretary, to ask whether an equality impact assessment would be published into proposed changes to winter fuel payments. He pointed out that in response to written parliamentary questions, ministers are obliged to respond with anything that they would release in response to freedom of information requests. The Ministerial Code states that ministers “should be as open as possible with Parliament and the public, refusing to provide information only when disclosure would not be in the public interest, which should be decided in accordance with the relevant statutes and the Freedom of Information Act 2000”. On Sept 12, the minister for pensions responded to Dr Evans’s written question, refusing to publish the information requested. However, the following day, after the House had risen for parliamentary recess, Ms Kendall’s department published the impact assessment in response to a freedom of information request. “This clearly breaches Cabinet Office guidance and possibly the Ministerial Code,” Mr Philp said. “It is appalling that on Sept 10, members of this House were asked to vote on the motion, while the equalities analysis that the Government released on Sept 13 was clearly available, but the Government chose to withhold it from members before the vote.” He went on to argue that he can “only conclude” the Government “deliberately withheld important information from the House, about a callous policy that will impact millions of our constituents”. Mr Philp said: “It chose only to make it available once the vote on the regulations had been won, and after Parliament had risen. As a result, there would not be a timely opportunity for members of this House to question the Government about the impact that cutting winter fuel payments will have on their constituents.” The impact assessment, published by the Government on Sept 13, revealed the groups of elderly people most likely to be affected by the Chancellor’s decision. It said that 1.6 million disabled people who currently receive the benefit – about 71 per cent – will lose out, alongside 2.7 million people aged 80 and above and 7.3 million aged between 66 and 79. The assessment concludes that couples are most likely to lose out, and that men are marginally more likely to be affected than women because they are less likely to be on the lowest incomes. what a bunch of cronies ... Mates of Ivy (Mr Morals) | inanaco | |
05/10/2024 15:40 | i am loz ... but its about perspective the car park is 36421.7 sqm not 80sqm and not big enough for a cricket pitch !! | inanaco | |
05/10/2024 15:38 | and the roof to this impressive Glass Works by the master is ? | inanaco | |
05/10/2024 15:35 | YOU'RE not a happy chappy are YOU | the real lozan | |
05/10/2024 15:30 | The cricket pitch 20m x 4m scaled by Subbuteo 7 years of hard toil to build with stones steps ... "regulation" probably not sounds like a building inspectors nightmare | inanaco | |
05/10/2024 14:37 | are you in shock yet Ivy as to what the lefties are doing they have already lost the next election ....😂 | inanaco | |
05/10/2024 14:29 | Afternoon Loz, Some people attitude to climate change is as hypocritical as Sun Tanning Entrepreneurs investing in a Company trying to cure melanoma. | ivyspivey | |
05/10/2024 14:23 | the proper way of doing it | inanaco | |
05/10/2024 14:11 | Actually Loz I have a lot of sympathy with your views on pseudo science. It seems particularly prevalent at the moment in climate models for example. The climate has always changed and even the founder of Greenpeace (now sacked) says that it is all massively exaggerated.I live a similar lifestyle to you albeit in Wales not France. I cut my own logs from my own trees and burn them in an old wood burning stove. Multiple sources though say that this has risks to health so it bothers me slightly. You are right, people have always done it but then they did not tend to live long did they.Mind you multiple sources, including Mr Milliband, suggest we need to capture carbon from power stations at massive expense when carbon dioxide is actually good for plant growth.Xylos | a0469514 | |
05/10/2024 12:11 | So - Before there was any 'Thinning of the ozone layer THAT causes melanoma' Was there such a thing as 'melanoma' ??? Or Am I, now responsible for all the 'fake scientific problems the world now faces' ??? Am I, now responsible for all the 'financial problems that UK now faces ??? Or Might Boris and the 'fingers in the till' PPE,Track n trace gang,that YOU voted for, that no one is being held to account for 'unrecoverable BILLIONS'... have something to do with it ??? Seems the 'new lot' are no better or worse than the 'old lot' . At least the sun often shines here on the S W France countryside | the real lozan | |
05/10/2024 11:34 | interesting phenomena A hole in the atmosphere ...... can we assume Lozan has never seen a circular vacuum ? while the rest of us have never heard of one or maybe i should translate that as ozone depletion triatomic molecule O3 toxic to us but it loves UV light which is even more toxic to us (certain wave lengths) The Thinning ozone layer causes melanoma !! | inanaco | |
05/10/2024 11:20 | Grouping like elementary school children to validate eachother and mock what you don't understand is the greatest testament to your stupidity. | sci102 | |
05/10/2024 10:55 | Oh another fool. Where did you come from? Nevermind, you are about to go back. | sci102 | |
05/10/2024 09:35 | Hi Bermuda, I would be hoping for two deals by Q1. I reckon the data from Scib/iScib will be enough for Big Pharma to make a move. Then we will have Modi-1 plus doublet data in H1. | marcusl2 | |
05/10/2024 09:10 | P S - Those who know least = Shout loudest Those who are have least ability in a skill.... end-up teaching it What's next for fake science ??? Will fake science prove that *You MUST wear the uniform* ??? | the real lozan | |
05/10/2024 09:06 | As we see here, those that know least on any subject always present technical 'scientific' reasoning to back their views. Always, someone else's 'scientific' reasoning... NEVER their own knwledge or experience. Mankind has been successfully burning wood for thousands, if not hundreds of thousands of years, learning through experience how to do it better. The 'trend' for 'take the cash scietists' to tell us all-based on their 'invented data' has become the norm. The hole in the atmosphere at the north pole The 'hottest days' since 'records' began....That are NOT Eggs are good for you, then they are not, then they are Not to mention 'the jibbyjab' Cars, or travel in general...is killing the planet Don't eat meat... eat insects ...science to save the planet The list of 'science backed' restrictions is endless Burning wood is now a killer . If man has been burning wood for hundreds of thousands of years = We/mankind should have died-out long ago. . Fake science.in the wrong hands, is a weapon that simply is used to *Restrict our FREEDOM' I, for one...Am not playing their game | the real lozan | |
05/10/2024 08:57 | Morning CT, First step is to get the great results which we all anticipate as without those the outlook here is severely compromised. I still feel given all the talk and history of how SCLP have operated then they will prefer to go it alone unless a real knockout offer comes in. My personal guess would be be the results will be very good and they may get some Glycan payments but they will decide to go it alone and that is the time to fully decide How to play this. | ivyspivey | |
05/10/2024 08:23 | It appears that Sci2 has a good look in the mirror this morning Bermuda, I agree with your comments about slippage etc | phoenixs | |
05/10/2024 06:36 | Actually averaging over time is a valid investment strategy but that doesn't mean it is applicable for every stock. The issue in this case is obvious, insanity mixed with poor intellect and a generous helping of narcissism. | sci102 | |
05/10/2024 05:34 | Talk of how to fund phase 2/3 The most likely outcome on good data would be a partner funding it including up front payments to Scancell. The risk/reward ratio would be very attractive to big pharma, especially BMS who have made billions in revenue from patent expiring therapies. There is also a potential number of payments due in the next 6 months or so. Genmab phase 1 Exclusivity Glymab deal New Glymab deals Avidity deals. There also seems to be a trend developing of a different non dilutive way to fund trials, high efficacy would likely be an interest to such methods | chilltime | |
04/10/2024 21:36 | marcus, Thanks for that. Looks like SCIB1 results will comfortably come before further funds are required, but they can't afford any further slippage on the iSCIB1+ or Modi1 results with results due in H1 and cash runway to Q3 2025. A glycan deal and/or Genmab milestone could obviously extend the cash runway but they don't want to be relying on that. | bermudashorts | |
04/10/2024 20:25 | FY24: Cash to deliver on key clinical catalysts Lighthouse | 24 September 2024 Focus remains on advancing the lead clinical assets SCIB1/iSCIB1+ and Modi-1, with trials ongoing for both. The clinical activity, plus preparations for future development, led to an increase in FY24 R&D spend (12 months to April) to £12.9m (FY23: £11.6m); G&A was £5.4m (FY23: £5.0m). The operating loss was wider at £18.3m vs FY23 £11.9m, as FY23 included a non-recurring £5.3m upfront from Genmab. Cash at end April of £14.8m (FY23: £19.9m) provides a runway through to calendar Q325, beyond key clinical data for SCIB1 in Q424, and iSCIB1+ and Modi-1 in H125. The next key clinical data expected in Q424 are for SCIB1 in combination with doublet checkpoint inhibitors (CPIs) in advanced melanoma (part of the second stage of the Phase II SCOPE study). The aim is to show that the SCIB1 combination can exceed currently achievable response rates (c 50%). This follows highly positive first stage data, where 11 of 13 patients achieved at least a partial response, exceeding the 70% target. Data for iSCIB1+ (improved second-generation construct that has been enhanced with AvidiMab, is more potent, and is capable of addressing all melanoma patients) are expected during H125. Both cohorts are expected to recruit up to 43 patients, with 36 currently in the SCIB1 cohort, and 27 in the iSCIB1+ cohort. A potentially registrational adaptive Phase II/III trial is currently being planned, with input from a clinical advisory board consisting of a panel of experts, which could start in 2025 subject to positive data and sufficient funds. In preparation for this trial, Scancell has scaled up manufacturing and has secured future supply of the currently used Stratis needle-free delivery system through a recent partnership with PharmaJet. Further data from the Phase I/II ModiFY trial of Modi-1 are expected H125. Key will be data from the recently initiated expansion cohort in renal cancer evaluating Modi-1 in combination with doublet checkpoint inhibitor therapy (ipilimumab plus nivolumab). Initial early signals of efficacy have already been observed in various monotherapy cohorts. The GlyMab platform could be a source of future deal(s), with two already in place; one with Genmab since 2022, and a more recent deal with an unnamed international biotech company (June 2024 Lighthouse). Trinity Delta view: Key upcoming SCIB1 data in advanced melanoma are largely de-risked given prior results, in our view, and Scancell is already preparing for future SCIB1/iSCIB1+ development, pending full SCOPE data, including from iSCIB1+ in H125. A potentially pivotal adaptive Phase II/III trial is being planned and critical elements to ensure rapid progression are being addressed. We believe this indicates confidence in the outcome of the ongoing SCOPE trial, appropriate in our view given prior data. Importantly, the current cash runway extends to Q325, beyond these SCIB1/iSCIB1+ milestones and Modi-1 data in H125; this could be extended through licensing activity. Our Scancell rNPV based valuation is £304m, or 33p/share. | marcusl2 | |
04/10/2024 20:20 | Nigel,Not a million miles, a mere 300. | ruckrover |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions